Purple Biotech CEO Efron to Transition in August 2026, Cash Runway Through 2027
Purple Biotech CEO Gil Efron will step down in August 2026 for health reasons, remaining in corporate development and on the board as the company launches a search for his successor. The company reported Q4 cash of $9.5M, securing runway into 2027, and took $20.5M impairments on CM24 and NT219.
1. CEO Transition
Purple Biotech announced that CEO Gil Efron will step down in August 2026 for health considerations, continue as a board director and lead corporate development, and support strategic partnerships while the board conducts a formal search for his successor.
2. Financial Results and Impairment
In Q4 2025, the company reported a $23.4M operating loss driven by a $20.5M non-cash impairment on CM24 and NT219, R&D expenses of $1.8M, and administrative expenses of $1.1M. Cash and equivalents totaled $9.5M at year-end, funding operations into 2027.
3. Pipeline Focus on CAPTN-3 Platform
The company advanced its CAPTN-3 tri-specific antibody platform, designating IM1305 as a development candidate and achieving toxicology and manufacturing milestones for IM1240. Preclinical data demonstrated expanded therapeutic window, in vivo anti-tumor efficacy, and scalable yield for the lead IM1240 asset.